Vincerx Pharma, Inc.

NasdaqCM VINC

Vincerx Pharma, Inc. Price to Book Ratio (P/B) on February 05, 2025

Vincerx Pharma, Inc. Price to Book Ratio (P/B) is NA on February 05, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Vincerx Pharma, Inc. 52-week high Price to Book Ratio (P/B) is NA on February 05, 2025, which is NA below the current Price to Book Ratio (P/B).
Vincerx Pharma, Inc. 52-week low Price to Book Ratio (P/B) is NA on February 05, 2025, which is NA below the current Price to Book Ratio (P/B).
Vincerx Pharma, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: VINC

Vincerx Pharma, Inc.

CEO	Dr. Raquel E. Izumi Ph.D.
IPO Date	May 27, 2020
Location	United States
Headquarters	260 Sheridan Avenue
Employees	42
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Key trends

Past 5 years